Evidence map›Paper›PMID 27818591›Full record

ArticleWorld journal of gastroenterology2016

Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis.

Yaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Svetlana Gingis-Velitski, Einat Almon, Yoseph Shaaltiel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
    Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yaron IlanYaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel.
Ami Ben Ya'acovYaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel.
Yehudit ShabbatYaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel.
Svetlana Gingis-VelitskiYaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel.
Einat AlmonYaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel.
Yoseph ShaaltielYaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel.
Hadassah Medical Center · ILProtalix BioTherapeutics (Israel) · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the immunomodulatory effect of oral administration of PRX-106 in the high-fat diet model.

methodsFor 22 wk, C57BL/6 HFD-fed mice received daily oral treatments with BY-2 cells expressing recombinant anti-tumor necrosis factor alpha fusion protein (PRX-106). Mice were followed for serum liver enzyme and triglyceride levels, liver histology and intrahepatic and systemic FACS.

resultsThe orally administered non-absorbable PRX-106 was biologically active. Altered distribution of CD4+CD25+FoxP3+ between the liver and spleen and an increase in the intrasplenic-to-intrahepatic CD4+CD25+FoxP3+ ratio and a decrease in the intrasplenic-to-intrahepatic CD8+CD25+FoxP3+ ratio were observed. An increase in intrahepatic NKT cells and a decrease in the intrasplenic-to-intrahepatic NKT ratio were noted. Assessment of the CD4-to-CD8 ratios showed sequestration of CD8+ lymphocytes in the liver. These effects were associated with a decrease in serum triglyceride levels, decrease in the aspartate aminotransferase levels, serum glucose levels, and HOMA-IR score. A decrease in hepatic triglycerides content was observed in the high dose-treated mice.

conclusionOrally administered PRX-106 shows biological activity and exerts an immunomodulatory effect, alleviating liver damage. The data suggest that PRX-106 may provide an oral immunotherapy for nonalcoholic steatohepatitis.

Indexed as

Administration, OralAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFlow CytometryForkhead Transcription FactorsImmunotherapyInterleukin-2 Receptor alpha SubunitLiverMaleMiceMice, Inbred C57BLNon-alcoholic Fatty Liver DiseasePlant CellsRecombinant Fusion ProteinsSpleenForkhead Transcription FactorsFoxp3 protein, mouseInterleukin-2 Receptor alpha SubunitRecombinant Fusion ProteinsTriglyceridesTumor Necrosis Factor-alphaDiabetesEnbrelNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisTumor necrosis alpha

Identifiers

PMID27818591
PMCPMC5075550
OpenAlexW2533846949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.